| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045090677 |
| P356 | DOI | 10.1038/NM1175 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nm1175 |
| P698 | PubMed publication ID | 15665834 |
| P5875 | ResearchGate publication ID | 8065494 |
| P50 | author | Yibin Wang | Q40664206 |
| P2093 | author name string | Djahida Bedja | |
| Kathleen L Gabrielson | |||
| Eiki Takimoto | |||
| David A Kass | |||
| Hunter C Champion | |||
| Shuxun Ren | |||
| E Rene Rodriguez | |||
| Manxiang Li | |||
| Diego Belardi | |||
| P2860 | cites work | Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells | Q28203141 |
| A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta ) and mediates protein kinase A-dependent inhibition of GSK-3beta | Q28216363 | ||
| A calcineurin-dependent transcriptional pathway for cardiac hypertrophy | Q28269300 | ||
| Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice | Q28362795 | ||
| Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure | Q28370616 | ||
| Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo | Q28511213 | ||
| Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A | Q28511919 | ||
| Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat | Q28567704 | ||
| Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice | Q28587028 | ||
| PDE5 is converted to an activated state upon cGMP binding to the GAF A domain | Q28593893 | ||
| Cardiac hypertrophy: the good, the bad, and the ugly | Q29615247 | ||
| Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study | Q33151248 | ||
| Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy | Q33974366 | ||
| MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. | Q34020904 | ||
| Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes | Q34038333 | ||
| Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice | Q34156036 | ||
| Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease | Q34214321 | ||
| Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore | Q34327908 | ||
| A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy | Q34486162 | ||
| Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. | Q34662451 | ||
| Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group | Q34747116 | ||
| Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death | Q34986193 | ||
| Cyclic GMP phosphodiesterases and regulation of smooth muscle function | Q35204728 | ||
| Nitric oxide and cardiac function: ten years after, and continuing | Q35213031 | ||
| Regulation of gene expression by cyclic GMP. | Q35596371 | ||
| Hypertrophy of the heart: a new therapeutic target? | Q35739349 | ||
| The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease | Q35846644 | ||
| Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. | Q39750341 | ||
| Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways | Q39750571 | ||
| The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice | Q40388321 | ||
| cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5 | Q41809117 | ||
| Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. | Q42450367 | ||
| Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure | Q42507993 | ||
| Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin | Q43660511 | ||
| Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance | Q43790689 | ||
| Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. | Q43843213 | ||
| Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. | Q43859254 | ||
| Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart | Q43954443 | ||
| Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity | Q44164556 | ||
| Time-dependent systolic and diastolic function in mice overexpressing calcineurin | Q44185537 | ||
| Phosphorylation of glycogen synthase kinase-3beta at serine-9 by phospholipase Cgamma1 through protein kinase C in rat 3Y1 fibroblasts | Q44276990 | ||
| Sildenafil citrate does not affect cardiac contractility in human or dog heart | Q44700632 | ||
| Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. | Q44748795 | ||
| cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism | Q45171610 | ||
| Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart | Q47951549 | ||
| PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects | Q57006372 | ||
| Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart | Q57396534 | ||
| Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways | Q64380804 | ||
| Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man | Q93921960 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 214-222 | |
| P577 | publication date | 2005-01-23 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy | |
| P478 | volume | 11 |
| Q60054773 | "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure" |
| Q38656290 | A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling. |
| Q59053624 | A big-hearted molecule |
| Q28513703 | A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension |
| Q84678814 | A murine experimental model for the mechanical behaviour of viable right-ventricular myocardium |
| Q24674156 | A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development |
| Q26850196 | A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation |
| Q90375261 | Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition |
| Q46843900 | Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients |
| Q33806059 | Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo. |
| Q61876962 | Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation |
| Q44338340 | Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis |
| Q33577023 | Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle |
| Q35994136 | Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction |
| Q38966016 | Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact |
| Q37730673 | Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease |
| Q84096219 | Alterations in cardiac structure and function in a murine model of chronic alcohol consumption |
| Q43858386 | Altered expression of the natriuretic peptide system in genetically modified heme oxygenase-1 mice treated with high dietary salt |
| Q37200751 | Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension |
| Q91988020 | Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA |
| Q89179169 | Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease |
| Q36042695 | Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension |
| Q34793299 | Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. |
| Q30417958 | Automated imaging reveals a concentration dependent delay in reversibility of cardiac myocyte hypertrophy |
| Q37589572 | Autonomic dysfunction in muscular dystrophy: a theoretical framework for muscle reflex involvement. |
| Q28397084 | Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches |
| Q45928477 | Benefits of PDE5 inhibition in patients with diastolic heart failure. |
| Q40374460 | Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure |
| Q42705343 | Brief Communication: Copper suppression of vascular endothelial growth factor receptor-2 is involved in the regression of cardiomyocyte hypertrophy |
| Q91771277 | Bronchiectasis and Focal Segmental Glomerulosclerosis in Rheumatoid Arthritis |
| Q51545876 | Can Nitrite AMPk Up Sirt-ainty to Treat Heart Failure With Preserved Ejection Fraction? |
| Q37742299 | Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment |
| Q30618651 | Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. |
| Q90331231 | Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure |
| Q38992600 | Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease |
| Q34160361 | Cardiac Z-disc signaling network |
| Q33966155 | Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects |
| Q26853363 | Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction |
| Q33777629 | Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes |
| Q36128551 | Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials |
| Q52652752 | Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy. |
| Q42475794 | Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload |
| Q52926690 | Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. |
| Q52691424 | Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice. |
| Q36164755 | Cardioprotective actions of cyclic GMP: lessons from genetic animal models |
| Q64276468 | Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease |
| Q42139180 | Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart |
| Q36544841 | Characterization of hsp27 kinases activated by elevated aortic pressure in heart. |
| Q37341337 | Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy. |
| Q35593122 | Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice |
| Q36042487 | Chronic hypoxia induces right heart failure in caveolin-1-/- mice. |
| Q37337837 | Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure |
| Q45870342 | Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling |
| Q46170789 | Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling |
| Q36835843 | Chronic sildenafil in men with diabetes and erectile dysfunction. |
| Q34152435 | Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. |
| Q37419185 | Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload |
| Q37657841 | Clinical and molecular genetics of the phosphodiesterases (PDEs). |
| Q43088929 | Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs |
| Q37543708 | Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy |
| Q60916640 | Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy |
| Q54976631 | Compartmentalized cyclic nucleotides have opposing effects on regulation of hypertrophic phospholipase Cε signaling in cardiac myocytes. |
| Q33769656 | Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II |
| Q42905360 | Controlling myocyte cGMP: phosphodiesterase 1 joins the fray |
| Q36380191 | Controversies in ventricular remodelling |
| Q28575727 | Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway |
| Q40053312 | Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. |
| Q36144664 | Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling |
| Q37632822 | Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation |
| Q37420916 | Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics |
| Q44924018 | Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte |
| Q33724430 | Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition |
| Q35812341 | Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes |
| Q34277031 | Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection |
| Q34668034 | Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes |
| Q52661743 | Decreasing Compensatory Ability of Concentric Ventricular Hypertrophy in Aortic-Banded Rat Hearts. |
| Q42364586 | Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors. |
| Q33786374 | Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease |
| Q35616023 | Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria |
| Q38440130 | Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction |
| Q37187366 | Diastolic heart failure: mechanisms and controversies |
| Q36267201 | Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice |
| Q48205666 | Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination. |
| Q33986250 | Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure |
| Q35680934 | Differential expression of PDE5 in failing and nonfailing human myocardium |
| Q33916555 | Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models |
| Q55379674 | Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP. |
| Q38191520 | ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models |
| Q37245523 | Effect of asymmetric dimethylarginine (ADMA) on heart failure development |
| Q37328507 | Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial |
| Q98658285 | Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension |
| Q42967773 | Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats |
| Q38263477 | Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension |
| Q35705494 | Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. |
| Q36360615 | Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis |
| Q46250539 | Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. |
| Q47617244 | Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension |
| Q40722411 | Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial |
| Q35500693 | Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. |
| Q37477116 | Enalapril attenuates the exaggerated sympathetic response to physical stress in prenatally programmed hypertensive rats |
| Q35887239 | Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling |
| Q33710298 | Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors |
| Q26853624 | Erectile dysfunction in heart failure patients: a critical reappraisal |
| Q90672985 | Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy |
| Q37893076 | Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy |
| Q38542767 | Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? |
| Q48403429 | Exercise pressor reflex function is altered in spontaneously hypertensive rats |
| Q38191440 | Exercise training in adverse cardiac remodeling |
| Q34508301 | Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease |
| Q37012737 | Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes |
| Q37591231 | Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity |
| Q38184790 | Fibroblast-mediated pathways in cardiac hypertrophy |
| Q82043755 | Fluorescent sensors for rapid monitoring of intracellular cGMP |
| Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
| Q55220754 | GDF11 Modulates Ca2+-Dependent Smad2/3 Signaling to Prevent Cardiomyocyte Hypertrophy. |
| Q52579764 | Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy. |
| Q37594085 | Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner |
| Q38764367 | Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. |
| Q33761721 | Heart failure and pulmonary hypertension |
| Q27000263 | Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies |
| Q37725106 | Heart failure with preserved ejection fraction: pathophysiology and emerging therapies |
| Q34664894 | Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment |
| Q35750972 | Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability |
| Q64078226 | High intensity training improves cardiac function in healthy rats |
| Q35140978 | Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity |
| Q36362712 | Host-mediated resolution of inflammation in periodontal diseases |
| Q43123689 | How does Viagra protect the ischemic heart? |
| Q33764751 | Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension |
| Q37162764 | Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension |
| Q35233153 | Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation |
| Q34732421 | Impaired ATP kinetics in failing in vivo mouse heart |
| Q35809052 | In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity |
| Q36364300 | In search of new therapeutic targets and strategies for heart failure: recent advances in basic science |
| Q34634339 | Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling |
| Q37075004 | Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis |
| Q27967859 | Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes |
| Q36512551 | Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure |
| Q46448829 | Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells |
| Q36118117 | Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy |
| Q36270020 | Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway. |
| Q26765931 | Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? |
| Q46711233 | Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium |
| Q33730630 | KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways |
| Q21090734 | KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways |
| Q36484609 | Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis |
| Q35128221 | Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes |
| Q54313660 | Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. |
| Q36108598 | Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease |
| Q35814877 | Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle |
| Q45053546 | Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. |
| Q34128868 | Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. |
| Q33594036 | Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration |
| Q37058008 | Looking to the future for erectile dysfunction therapies |
| Q37331898 | Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. |
| Q37648508 | M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics |
| Q94476078 | Managing heart failure with preserved ejection fraction |
| Q58792303 | Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease |
| Q37108093 | Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure |
| Q24648818 | Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats |
| Q63131766 | Mechanisms of physiological and pathological cardiac hypertrophy |
| Q58703037 | MiR-665 aggravates heart failure via suppressing CD34-mediated coronary microvessel angiogenesis |
| Q52718816 | MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. |
| Q34973841 | Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog |
| Q46061154 | Mitochondrial nitric oxide metabolism during rat heart adaptation to high altitude: effect of sildenafil, L-NAME, and L-arginine treatments |
| Q37329891 | Modulation of cGMP in heart failure: a new therapeutic paradigm |
| Q36296869 | Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate |
| Q38038531 | Molecular and cellular basis for diastolic dysfunction |
| Q41855920 | Molecular pathways underlying cardiac remodeling during pathophysiological stimulation |
| Q24619376 | Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts |
| Q24641873 | Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation |
| Q52687612 | Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. |
| Q53243126 | Murine cardiac growth, TRPC channels, and cGMP kinase I. |
| Q37688943 | Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner |
| Q42090791 | Myocardial effects of PDE5 inhibition: more function with less mass |
| Q42094814 | Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. |
| Q38780883 | Myocardial reverse remodeling: how far can we rewind? |
| Q36425960 | Natriuretic peptides as therapeutic targets |
| Q55331921 | Nitric oxide and pulmonary arterial hypertension. |
| Q43267893 | Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway |
| Q49501122 | Nitric oxide signalling in cardiovascular health and disease. |
| Q37917873 | Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling |
| Q26830146 | Nitric oxide synthases in heart failure |
| Q38645950 | Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. |
| Q46659772 | Normal and high eNOS levels are detrimental in both mild and severe cardiac pressure-overload |
| Q26765793 | Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology |
| Q26746978 | Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012 |
| Q37075920 | Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. |
| Q34664054 | Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts |
| Q36379338 | Optimizing postoperative sexual function after radical prostatectomy |
| Q34105975 | Oxidative stress regulates left ventricular PDE5 expression in the failing heart |
| Q37417757 | PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction. |
| Q33872491 | PDE5 inhibitor efficacy is estrogen dependent in female heart disease |
| Q35827798 | PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer |
| Q36878017 | PDE5 inhibitors beyond erectile dysfunction |
| Q37622381 | PDE5 inhibitors: in vitro and in vivo pharmacological profile. |
| Q46927614 | PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation |
| Q37727128 | PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. |
| Q30494729 | PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation |
| Q84565654 | PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization |
| Q91284093 | PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress |
| Q37361545 | PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury |
| Q28583542 | Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart |
| Q36191580 | Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling |
| Q54968385 | Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct. |
| Q37910906 | Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy |
| Q39004036 | Periodontitis and myocardial hypertrophy |
| Q38128886 | Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment |
| Q37058596 | Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. |
| Q41927225 | PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design |
| Q90252283 | Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure |
| Q36080545 | Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway |
| Q41045943 | Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation. |
| Q35049171 | Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension |
| Q37291307 | Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway |
| Q64077122 | Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure |
| Q37450782 | Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications |
| Q37497840 | Phosphodiesterase 5 inhibitors: are they cardioprotective? |
| Q37245123 | Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. |
| Q46721337 | Phosphodiesterase 5A as a target in cardiac disease |
| Q35879351 | Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines |
| Q24323316 | Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease |
| Q41819549 | Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy |
| Q37733556 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction |
| Q47171803 | Phosphodiesterase type 5 and cancers: progress and challenges |
| Q36460566 | Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications |
| Q57822691 | Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro |
| Q28510096 | Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function |
| Q54750527 | Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention. |
| Q36314042 | Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction |
| Q51742615 | Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? |
| Q34808466 | Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity |
| Q27692588 | Phosphodiesterases and cardiac cGMP: evolving roles and controversies |
| Q38033089 | Phosphodiesterases and cyclic GMP regulation in heart muscle |
| Q33799926 | Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition |
| Q38854987 | Physiological and pathological cardiac hypertrophy. |
| Q42741838 | Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload |
| Q37329709 | Potential novel pharmacological therapies for myocardial remodelling |
| Q37245076 | Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition |
| Q34686759 | Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation |
| Q35214761 | Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors |
| Q54121051 | Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. |
| Q35836147 | Prevention of PKG1α oxidation augments cardioprotection in the stressed heart. |
| Q37696624 | Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. |
| Q37157104 | Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension |
| Q28084015 | Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil |
| Q36812656 | Profilin modulates sarcomeric organization and mediates cardiomyocyte hypertrophy. |
| Q34421211 | Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects |
| Q38670275 | Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials |
| Q42133076 | Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo |
| Q37142904 | Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. |
| Q39404378 | Proteostasis in cardiac health and disease. |
| Q37409709 | Pulmonary Hypertension in Heart Failure Patients Presenting at OAUTHC, Ile-Ife, Nigeria |
| Q37328944 | Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study |
| Q45398906 | Pulmonary hypertension in hypertensive patients: association with diastolic dysfunction and increased pulmonary vascular resistance |
| Q36208949 | Quantitative analysis of the chromatin proteome in disease reveals remodeling principles and identifies high mobility group protein B2 as a regulator of hypertrophic growth |
| Q92489474 | Recent advances in Duchenne muscular dystrophy |
| Q36473369 | Recent insights into cardiac hypertrophy and left ventricular remodeling. |
| Q26800060 | Redox regulation of cGMP-dependent protein kinase Iα in the cardiovascular system |
| Q36281111 | Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets |
| Q34048214 | Regulatable atrial natriuretic peptide gene therapy for hypertension |
| Q30381503 | Regulation of Mitochondrial Dynamics by Dynamin-Related Protein-1 in Acute Cardiorenal Syndrome |
| Q35050007 | Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted mice |
| Q29615166 | Regulation of cardiac hypertrophy by intracellular signalling pathways |
| Q28594677 | Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice |
| Q93051737 | Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System |
| Q36412738 | Regulatory Forum Opinion Piece*: Imaging Applications in Toxicologic Pathology-Recommendations for Use in Regulated Nonclinical Toxicity Studies. |
| Q36770499 | Relevance of nitric oxide for myocardial remodeling. |
| Q84891083 | Remodelling and adverse remodelling in CAD |
| Q36877595 | Rescue of Pressure Overload-Induced Heart Failure by Estrogen Therapy |
| Q90588213 | Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary |
| Q37040082 | Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy |
| Q37964927 | Reverse remodeling in heart failure--mechanisms and therapeutic opportunities |
| Q36815996 | Reversing chronic remodeling in heart failure |
| Q35725663 | Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? |
| Q42829730 | Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension |
| Q37996857 | Rodent models of heart failure: an updated review. |
| Q33577131 | Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy |
| Q30575578 | Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. |
| Q41865010 | Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis |
| Q36539476 | Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension |
| Q55416779 | Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction. |
| Q34144673 | Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. |
| Q40580301 | Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine |
| Q52886208 | Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. |
| Q39118050 | Sex Differences in Metabolic Cardiomyopathy |
| Q33872473 | Sex, drugs, and trial design: sex influences the heart and drug responses |
| Q26825154 | Signaling effectors underlying pathologic growth and remodeling of the heart |
| Q64921288 | Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase. |
| Q30385717 | Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model |
| Q54117420 | Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. |
| Q61918737 | Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction Trial: Rationale and Design |
| Q24655371 | Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency |
| Q37258804 | Sildenafil and phosphodiesterase-5 inhibitors for heart failure |
| Q37747432 | Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells |
| Q21559608 | Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress |
| Q34315276 | Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. |
| Q54502027 | Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. |
| Q34558395 | Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury |
| Q41943188 | Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration |
| Q37018954 | Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence |
| Q34013874 | Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction |
| Q35141990 | Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles |
| Q35699243 | Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. |
| Q34279254 | Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. |
| Q97884505 | Sildenafil reverses the hypertrophy of mice right ventricle caused by hypoxia but does not reverse the changes in the myosin heavy chain isoforms |
| Q34300912 | Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload |
| Q36234101 | Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation. |
| Q47864098 | Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload |
| Q45305137 | Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study |
| Q35665744 | Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension |
| Q47369973 | Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction |
| Q53589410 | Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. |
| Q37310691 | Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1 |
| Q36554423 | Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. |
| Q93054062 | Small animal models of heart failure |
| Q36887547 | Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface |
| Q34801292 | Steroid-sensitive gene 1 is a novel cyclic GMP-dependent protein kinase I substrate in vascular smooth muscle cells |
| Q93633598 | Straight to the heart with Viagra |
| Q26749044 | Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists |
| Q30539041 | Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I |
| Q37339495 | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors. |
| Q92891438 | Swimming exercise inhibits myocardial ER stress in the hearts of aged mice by enhancing cGMP‑PKG signaling |
| Q52574407 | Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. |
| Q27013000 | Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy |
| Q38537087 | Systems biological approaches to the cardiac signaling network |
| Q92257319 | TRPC Channels in Proteinuric Kidney Diseases |
| Q37089726 | Tackling heart failure in the twenty-first century |
| Q35635261 | Tadalafil, a Phosphodiesterase Inhibitor Protects Stem Cells over Longer Period Against Hypoxia/Reoxygenation Injury Through STAT3/PKG-I Signaling |
| Q48849818 | Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. |
| Q37876521 | Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling |
| Q33863759 | Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. |
| Q36268310 | Targeting calcineurin and associated pathways in cardiac hypertrophy and failure |
| Q99587532 | Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? |
| Q34252901 | Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications |
| Q38099859 | Targeting nitric oxide in the subacute restorative treatment of ischemic stroke |
| Q39141728 | Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure |
| Q38688194 | Targets for Heart Failure With Preserved Ejection Fraction. |
| Q37119356 | Tetrahydrobiopterin |
| Q28551385 | The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities |
| Q92736271 | The Popeye domain containing gene family encoding a family of cAMP-effector proteins with important functions in striated muscle and beyond |
| Q54489074 | The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38. |
| Q55071550 | The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. |
| Q38751389 | The associations among co-morbidity, cardiac geometries and mechanics in hospitalized heart failure with or without preserved ejection fraction. |
| Q27024279 | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction |
| Q38971075 | The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. |
| Q42989291 | The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis. |
| Q37121202 | The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure |
| Q36500200 | The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems |
| Q41859742 | The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study |
| Q35184655 | The effects of tadalafil on renal ischemia reperfusion injury: an experimental study |
| Q36567862 | The emerging role for type 5 phosphodiesterase inhibition in heart failure |
| Q28543897 | The emperor's new clothes: PDE5 and the heart |
| Q33849050 | The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences |
| Q28544798 | The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial |
| Q89668767 | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| Q42701201 | The involvement of vimentin in copper-induced regression of cardiomyocyte hypertrophy |
| Q34807853 | The overexpression of Twinkle helicase ameliorates the progression of cardiac fibrosis and heart failure in pressure overload model in mice |
| Q46785598 | The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size |
| Q38123147 | The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload |
| Q42557861 | The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. |
| Q35156618 | The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases |
| Q34485166 | The sarcomeric Z-disc: a nodal point in signalling and disease |
| Q36291007 | The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs |
| Q89704968 | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| Q87037570 | Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy |
| Q27005761 | Therapeutic potential of PDE modulation in treating heart disease |
| Q37565374 | Titin-based mechanical signalling in normal and failing myocardium |
| Q46717362 | Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice |
| Q42411588 | TrACEing angiotensin II type 1 to right ventricular hypertrophy: are the "sartans" a viable course to treating pulmonary arterial hypertension? |
| Q38235602 | Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction |
| Q86627147 | Treatment for pulmonary hypertension due to left heart diseases |
| Q35016271 | Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? |
| Q51539883 | Treatment of pulmonary hypertension. |
| Q41902396 | Treatment with Sildenafil and Donepezil Improves Angiogenesis in Experimentally Induced Critical Limb Ischemia. |
| Q38950512 | UPS Activation in the Battle Against Aging and Aggregation-Related Diseases: An Extended Review |
| Q38663141 | Ubiquitin and ubiquitin-like proteins in cardiac disease and protection |
| Q28304882 | Ubiquitin-proteasome system and hereditary cardiomyopathies |
| Q38695797 | VEGFB-VEGFR1 ameliorates Ang II-induced cardiomyocyte hypertrophy through Ca(2+) -mediated PKG I pathway. |
| Q51533381 | Vasostatin-1 Stops Structural Remodeling and Improves Calcium Handling via the eNOS-NO-PKG Pathway in Rat Hearts Subjected to Chronic β-Adrenergic Receptor Activation. |
| Q30548444 | Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice |
| Q36980906 | Ventricular-vascular interaction in heart failure |
| Q45251692 | Viagra: now mending hearts |
| Q33783174 | Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure |
| Q53648300 | Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. |
| Q42690112 | alpha1G-dependent T-type Ca2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice |
| Q46011268 | cGKI signaling in cardiac hypertrophy. |
| Q55004774 | cGMP Signaling in the Cardiovascular System-The Role of Compartmentation and Its Live Cell Imaging. |
| Q54978990 | cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. |
| Q37980659 | cGMP becomes a drug target |
| Q45928353 | cGMP kinase I, cardiac hypertrophy and PDE inhibition. |
| Q43066343 | cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications |
| Q34244951 | cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action |
| Q36127830 | cGMP-dependent protein kinases in drug discovery |
| Q37312871 | cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium |
| Q45928953 | cGMP-mediated antioxidant signaling: a role for the c-Abl tyrosine kinase. |
| Q35978243 | cGMP/Protein Kinase G Signaling Suppresses Inositol 1,4,5-Trisphosphate Receptor Phosphorylation and Promotes Endoplasmic Reticulum Stress in Photoreceptors of Cyclic Nucleotide-gated Channel-deficient Mice |
| Q38220091 | cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications |
| Q41693992 | miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. |
| Q35087054 | sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling |
Search more.